Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MXCT
stocks logo

MXCT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
9.30M
+6.96%
-0.080
-20%
8.84M
-14.92%
-0.060
-40%
8.93M
+4.96%
-0.060
-50%
Estimates Revision
The market is revising Downward the revenue expectations for MaxCyte, Inc. (MXCT) for FY2025, with the revenue forecasts being adjusted by -2.73% over the past three months. During the same period, the stock price has changed by 12.06%.
Revenue Estimates for FY2025
Revise Downward
down Image
-2.73%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-7.7%
In Past 3 Month
Stock Price
Go Up
up Image
+12.06%
In Past 3 Month
Wall Street analysts forecast MXCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MXCT is 6.92 USD with a low forecast of 4.94 USD and a high forecast of 8.89 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast MXCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MXCT is 6.92 USD with a low forecast of 4.94 USD and a high forecast of 8.89 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.580
sliders
Low
4.94
Averages
6.92
High
8.89
Current: 1.580
sliders
Low
4.94
Averages
6.92
High
8.89
BTIG
BTIG
Buy
to
Neutral
downgrade
2025-08-11
Reason
BTIG
BTIG
Price Target
2025-08-11
downgrade
Buy
to
Neutral
Reason
BTIG downgraded MaxCyte to Neutral from Buy without a price target after "a tough Q2 business update" and lowering of the bar for 2025. MaxCyte lowered its 2025 revenue guide by $5M, or 14% of its business, citing ongoing challenges for many of its cell and gene therapy customers to obtain capital to fund programs, purchase capital, or lease its systems, the analyst noted. The firm thinks the company still has a best-in-class electroporation platform, arguing that the "number one driver to turn the business around is simply its customers becoming more readily able to raise money and invest in more programs."
William Blair
Matt Larew
Outperform -> Market Perform
downgrade
2025-08-07
Reason
William Blair
Matt Larew
Price Target
2025-08-07
downgrade
Outperform -> Market Perform
Reason
William Blair analyst Matt Larew downgraded MaxCyte to Market Perform from Outperform following the earnings report. The company reported a miss and guidance reduction in a strong bioprocessing tools tape, the analyst tells investors in a research note. The firm attributes the miss to MaxCyte's customer exposure and less visible revenue profile. William Blair believes the company's visibility seems lower than peers.
Stephens
Stephens
Overweight
initiated
$6
2025-07-21
Reason
Stephens
Stephens
Price Target
$6
2025-07-21
initiated
Overweight
Reason
Stephens initiated coverage of MaxCyte with an Overweight rating and $6 price target. The company is in the early stages of making prudent investments in offerings that expand its reach of the market, the analyst tells investors in a research note. The firm added that while this strategy is still in the early innings, it believe the strategy has the potential to drive long-term revenue growth.
Stifel
Daniel Arias
Strong Buy
Maintains
$11 → $9
2025-03-12
Reason
Stifel
Daniel Arias
Price Target
$11 → $9
2025-03-12
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for MaxCyte Inc (MXCT.O) is -6.16, compared to its 5-year average forward P/E of -16.63. For a more detailed relative valuation and DCF analysis to assess MaxCyte Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-16.63
Current PE
-6.16
Overvalued PE
-0.94
Undervalued PE
-32.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-16.95
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
7.79
Undervalued EV/EBITDA
-41.69

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
12.50
Current PS
0.00
Overvalued PS
20.32
Undervalued PS
4.67
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MXCT News & Events

Events Timeline

(ET)
2025-11-12
17:17:19
MaxCyte's CFO Douglas Swirsky to Step Down from Position
select
2025-11-12
17:01:32
MaxCyte confirms FY25 revenue forecast to be steady or decrease by 10% compared to the previous year.
select
2025-11-12
16:52:21
MaxCyte Announces Q3 Earnings Per Share of 12 Cents, Exceeding Consensus Estimate of 9 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-01Newsfilter
Cellares Appoints New CCO to Support 2026 Clinical Trials
  • Executive Appointment: Cellares has appointed Ali Soleymannezhad as Chief Commercial Officer, who brings over 20 years of commercialization experience in cell therapy and bioprocessing, aimed at driving the company's global commercial strategy in preparation for clinical trials in 2026.
  • Global Partnership Agreements: Cellares has signed multiple global manufacturing agreements with partners including Bristol Myers Squibb and Kite, establishing its leadership in cell therapy manufacturing and laying the groundwork for a future IPO.
  • Technological Innovation: Cellares' Cell ShuttleTM has received FDA's Advanced Manufacturing Technology designation, providing expedited review and regulatory support to lower manufacturing costs and accelerate global market entry for cell therapies.
  • Market Expansion: Cellares plans to establish a network of IDMO Smart Factories across the U.S., Europe, and Japan, which is expected to increase the batch output of each factory by tenfold, thereby meeting global patient demand for cell therapies.
[object Object]
Preview
4.5
09-23Newsfilter
MaxCyte Unveils Operational Restructuring Aimed at Cost Reduction and Faster Profitability

  • Workforce Reduction Announcement: MaxCyte, Inc. is restructuring its operations, resulting in a 34% reduction of its global workforce to align resources with strategic priorities, aiming for annualized savings of approximately $13.6 million.

  • Financial Outlook: The company anticipates flat to a 10% decline in core revenue for 2025 compared to 2024, while expecting around $5 million in SPL program-related revenue and a year-end cash position of at least $155 million.

[object Object]
Preview
4.0
08-11Benzinga
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

  • Analyst Downgrades: Several Wall Street analysts downgraded their ratings on various companies, including The Trade Desk, C3.ai, Aspen Aerogels, MaxCyte, and Universal Electronics, with significant reductions in price targets.

  • Current Stock Performance: As of the latest market close, shares of these companies showed varying performance, with The Trade Desk at $54.23, C3.ai at $22.13, Aspen Aerogels at $7.55, MaxCyte at $1.38, and Universal Electronics at $5.00.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is MaxCyte Inc (MXCT) stock price today?

The current price of MXCT is 1.58 USD — it has increased 3.95 % in the last trading day.

arrow icon

What is MaxCyte Inc (MXCT)'s business?

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

arrow icon

What is the price predicton of MXCT Stock?

Wall Street analysts forecast MXCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MXCT is 6.92 USD with a low forecast of 4.94 USD and a high forecast of 8.89 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is MaxCyte Inc (MXCT)'s revenue for the last quarter?

MaxCyte Inc revenue for the last quarter amounts to 6.83M USD, decreased -16.35 % YoY.

arrow icon

What is MaxCyte Inc (MXCT)'s earnings per share (EPS) for the last quarter?

MaxCyte Inc. EPS for the last quarter amounts to -0.12 USD, increased 9.09 % YoY.

arrow icon

What changes have occurred in the market's expectations for MaxCyte Inc (MXCT)'s fundamentals?

The market is revising Downward the revenue expectations for MaxCyte, Inc. (MXCT) for FY2025, with the revenue forecasts being adjusted by -2.73% over the past three months. During the same period, the stock price has changed by 12.06%.
arrow icon

How many employees does MaxCyte Inc (MXCT). have?

MaxCyte Inc (MXCT) has 114 emplpoyees as of December 05 2025.

arrow icon

What is MaxCyte Inc (MXCT) market cap?

Today MXCT has the market capitalization of 168.54M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free